Loading…
Chinese cosmetics company known for eye-care and anti-aging skincare products under the Marubi brand.
Chinese cosmetics company known for eye-care and anti-aging skincare products under the Marubi brand.
Sells its skincare through online platforms and offline counters, with eye cream the product that built the brand and newer brands added to widen the range. It is founder-controlled.
In one line: A Chinese anti-aging/eye-care skincare brand.
Moat: narrow (brand). Recognized eye-care skincare niche brand versus larger diversified beauty competitors.
Headquarters: Guangzhou, China · Employees: 1,380
Size Guangdong Marubi Biotechnology (603983.SS) is a China Consumer Staples company (Household/Personal Care) with a market value of $1.45B, the 1672nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥24.22 on 6 Nov 2026.
Performance Over six months the shares fell 3.8%, against +1.4% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 6.5% over the last twelve months (peer median +7.0%); the operating margin is 1.8% (peer median 9.2%).
Valuation It trades at 37.0× forward earnings against a peer median of 19.4× (4th most expensive of 21).
Capital Return on invested capital runs 3.6 points below its cost of capital (7.5% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.24B | CN¥3.44B | CN¥2.95B | CN¥2.21B | CN¥1.71B |
| Revenue growth | — | +17% | +34% | +29% | — |
| Gross profit | CN¥2.41B | CN¥2.51B | CN¥2.16B | CN¥1.55B | CN¥1.15B |
| EBITDA | n/a | CN¥294M | CN¥369M | CN¥201M | CN¥175M |
| Net income | CN¥141M | CN¥247M | CN¥342M | CN¥259M | CN¥174M |
| Free cash flow | -CN¥62.3M | CN¥72.4M | -CN¥6.50M | CN¥115M | -CN¥57.0M |
| Capital expenditure | CN¥162M | CN¥205M | CN¥321M | CN¥260M | CN¥114M |
| Total debt | CN¥457M | CN¥398M | CN¥794M | CN¥255M | CN¥285M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guangdong Marubi Biotechnology 603983.SS | $1.45B | -4% | -6% | 2% | 37.0× | n/a |
| Proya Cosmetics 603605.SS | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% |
| Yunnan Botanee Bio-Technology 300957.SZ | $1.84B | -28% | +7% | 9% | 21.2× | 4.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603983.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.3% | +2.3% | 5th lowest of 21 |
| 6-month return | -3.8% | +1.4% | 9th lowest of 21 |
| Distance from 52-week high | -34.6% | -26.6% | 8th lowest of 21 |
| Revenue growth (TTM) | -6.5% | +7.0% | 2nd lowest of 21 |
| Operating margin | 1.8% | 9.2% | 2nd lowest of 21 |
| Forward P/E | 37.0× | 19.4× | 4th most expensive of 21 |
| ROIC minus cost of capital | -3.6 pp | +5.7 pp | 4th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangdong Marubi Biotechnology 603983.SS | China | $1.45B | -4% | -6% | 2% | 37.0× | n/a | n/a |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.49B | +25% | 0% | 3% | 41.2× | 30.6% | +22.8% |
| Intercos ICOS.MI | Italy | $1.50B | +16% | -5% | 9% | 19.5× | 4.5% | +11.5% |
| AMOREPACIFIC 002790.KS | South Korea | $1.55B | -3% | +9% | 9% | 8.4× | -17.9% | -1.3% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.58B | -30% | +28% | 20% | 22.5× | 8.7% | +3.6% |
| d'Alba Global 483650.KS | South Korea | $1.32B | -37% | +55% | 21% | 13.6× | -2.2% | +53.0% |
| Energizer ENR | United States | $1.63B | +26% | +2% | 16% | 7.2× | -5.2% | +1.5% |
| Edgewell Personal Care EPC | United States | $1.29B | +32% | -7% | 6% | 12.4× | 4.1% | +2.7% |
| Pigeon 7956.T | Japan | $1.66B | +30% | +7% | 13% | 26.3× | -1.3% | +1.9% |
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.22B | -52% | +23% | 8% | 15.0× | -5.9% | +21.2% |
| Shanghai Jahwa United 600315.SS | China | $1.74B | -13% | +9% | 2% | 18.1× | 17.1% | -2.1% |
| Emami EMAMILTD.NS | India | $1.80B | -15% | +3% | 20% | 21.4× | 21.7% | +5.6% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.84B | -28% | +7% | 9% | 21.2× | 4.5% | +15.3% |
| Blue Moon 6993.HK | Hong Kong | $1.88B | -15% | -2% | -2% | 93.6× | n/a | n/a |
| Kolmar Korea 161890.KS | South Korea | $1.89B | +23% | +13% | 10% | 13.0× | -0.9% | +15.5% |
| Pola Orbis 4927.T | Japan | $1.96B | +8% | +1% | 10% | 28.8× | -3.1% | -0.7% |
| Shanghai Forest Cabin Cosmetics 2657.HK | Hong Kong | $1.06B | 0% | +74% | 18% | 12.1× | 11.5% | +49.0% |
| SYoung 300740.SZ | China | $1.00B | -37% | +14% | 3% | 39.6× | 18.1% | +6.1% |
| Cosmax 192820.KS | South Korea | $2.13B | +21% | +16% | 8% | 16.6× | n/a | n/a |
| KOSE 4922.T | Japan | $2.16B | +7% | +3% | 4% | 27.2× | n/a | n/a |
| Noevir 4928.T | Japan | $977M | +3% | +1% | 16% | 19.4× | -4.8% | +4.5% |